The UK's ImmuPharma PLC is insisting that its investigational lupus drug Lupuzor (forigerimod) still represents a “significant opportunity” despite extremely disappointing top-line results from a much-anticipated Phase III trial.
ImmuPharma Puts On Very Brave Face After Lupus Drug Flop
Shares in the UK biotech have fallen through the floor following a failed Phase III trial of Lupuzor but ImmuPharma remains surprisingly upbeat about the lupus drug's prospects.

More from Immunological
More from Therapy Areas
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.